Becomes go-to AI intelligence layer and clinical decision support tool across 100+ hospitals NEWARK, N.J., Feb. 19, 2026 /PRNewswire/ -- Wellsheet, a leader in AI clinical workflows and operations, was recently named one of 2025's most promising startups. Wellsheet is gaining traction as hospitals grapple with clinician burnout and data overload. Its technology is live…
Read More
IVIEW Therapeutics announced today that its innovative gene therapy candidate GVB-2001 has successfully completed treatment of the first patient with primary open-angle glaucoma (POAG), marking a key clinical milestone and opening a new chapter for glaucoma management unconstrained by patient-specific genetic backgrounds. The procedure was performed under the direction of…
Read More
IVIEW Therapeutics (“IVIEW”) today announced that its investigational ophthalmic drug, IVIEW-1201D, has received U.S. Food and Drug Administration (FDA) Phase III IND clearance for the treatment of adenoviral conjunctivitis. This important milestone marks the program’s entry into a new phase of global, pivotal clinical development and represents a major step…
Read More
PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company pioneering innovative cell therapies, today announced it will share interim clinical data from its Phase 1 first-in-human study of VIPER-101, a CD5-modulated autologous CAR-T therapy for patients with relapsed or refractory (r/r) T-cell lymphoma (TCL), in…
Read More
Healthcare is transforming rapidly, driven by technological advancements, evolving patient expectations and shifting demographics. While these changes propel our industry forward, significant gaps in access continue. As we enter this new era, it is critical that we partner with clinicians across the industry to constantly explore new ways to optimize.…
Read More
Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Allschwil, Switzerland, September 25, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections,…
Read More
IVIEW Therapeutics is pleased to announce the appointment of Jeanette Stewart, RN, as the Director of Clinical Operations Bringing more than 30 years of expertise in ophthalmic clinical research, Ms. Stewart is a seasoned professional who has successfully managed clinical trials across all stages of development. She is the CEO…
Read More
First Patient Dosed in Phase 2b Clinical Trial of IVW-1001 for Dry Eye Disease IVIEW Therapeutics today announced that the first patient has been dosed in its Phase 2b clinical trial evaluating IVW-1001, a novel topical therapy for dry eye disease. The initial dosing was conducted at the Eye Research…
Read More
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement…
Read More
IVIEW Therapeutics Presents Breakthrough GVB-2001 Gene Therapy for Glaucoma at CCRVO The 13th Congress of Chinese Research in Vision and Ophthalmology (CCRVO), jointly organized by the Chinese Medical Association and its Ophthalmology Branch, was held in Chongqing from July 24–27, 2025. As one of the two premier Category I academic…
Read More